Abstract
Objective
To investigate the effect of concomitantly administered curcumin on the pharmacokinetics of the β1 adrenoceptor blocker talinolol.
Methods
The study was conducted in a self-controlled, two-period experiment with a randomized, open-labeled design, using 12 healthy volunteers and a wash out period of 1 week between the administration of a single oral dose of 50 mg talinolol and the concomitant administration of curcumin (300 mg day−1 for 6 days) and a single oral dose of 50 mg talinolol on the seventh day. Concentrations of talinolol were measured in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. Non-compartmental analysis was used to characterize talinolol plasma concentration-time profiles, all pharmacokinetic parameters were calculated using DAS (ver. 2.0) software, and comparisons of mean values were analyzed by the Wilcoxon signed rank test. Differences were considered to be significant at p < 0.05 (two-sided test).
Results
The consumption of curcumin for 6 days reduced the area under the curve (AUC) from predose to infinity (\( {\text{AUC}}_{{{\text{0}} - \infty }} \)) of talinolol from 1860.0 ± 377.9 to 1246.0 ± 328.2 ng.h mL−1, the highest observed concentration values (Cmax) were significantly decreased from 147.8 ± 63.8 to 106.4 ± 39.9 ng mL−1, and the CL/F was increased from 27.9 ± 5.5 to 43.1 ± 13.4 L.h−1 (p < 0.05). There was no significant difference in sampling time for Cmax (tmax) and elimination half-life (t1/2) values between the two periods (p > 0.05). The interindividual variability in AUC0–60 and Cmax of talinolol was comparable in two study periods; the coefficient of variance (CV) of AUC0–60 and Cmax was 26 and 40% after curcumin versus 21 and 43% after talinolol alone, respectively.
Conclusion
We suggest that the reduced bioavailability of talinolol is most probably due to the low intraluminal curcumin concentration, or possibly due to the upregulation of further ATP-binding cassette transporters, such as MRP2, in different tissues.
Similar content being viewed by others
References
Campeanu A (2001) The cardiac insufficiency talinolol study (CITAS) study design. Eur J Heart Fail 3:377–380
Assmann I (1995) The actions of talinolol, a beta 1-selective beta blocker, in cardiac arrhythmia and acute myocardial infarction. Curr Med Res Opin 13:325–342
Maurer HH, Tenberken O, Kratzsch C (2004) Screening for library-assisted identification and fully validated quantification of 22 beta-blockers in blood plasma by liquid chromatography-mass spectrometry with atmospheric pressure chemical ionization. J Chromatogr A 1058:169–181
Weigmann I, Terhaag B (1995) Cordanum on target: a beta-blocker time tested and up-to date. Pharmedicum 3:216–220
Campeanu A, Olinescu R, Vasile M (1999) Effects of talinolol, a cardioselective betablocker on the oxidative stress in the cigarette smokers. Cardiovasc Drugs Ther 13:68–71
Campeanu A, Olinescu R, Vasile M (1999) Effects of talinolol, aβ1-selective betablocker on the oxidative stress in post unstable angina. Cardiovasc Drugs Ther 13:19–23
Beate T, Oertel R, Richter K et al (1995) Disposition and bioavailability of theβ1-adrenoceptor antagonist talinolol in man. Biopharm Drug Dispos 16:403–414
Gramatte T, Oertel R, Terhaag B (1996) Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans. Clin Pharmacol Ther 59:541–549
Krueger M, Achenbach H, Terhaag B (2001) Pharmacokinetics of oral talinolol following a single dose and during steady state in patients with chronic renal failure and healthy volunteers. Int J Clin Pharm Ther 39:61–66
Ulrike W, Hildegard SL, Ernst M (1996) Evidence for intestinal secretion as an additional clearance pathway of talinolol enatiomers: concentration- and dose-dependent absorption in vitro and in vivo. Pharm Res 13:514–522
Werner S, Karen L, Georg E (2003) Variability of intestinal expression of p-glycoprotein in healthy volunteers as described by absorption of talinolol from four bioequivalent tablets. J Pharm Sci 92:560–566
Schwarz UI, Gramatte T, Krappweis J (2000) P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int J Clin Pharm Ther 38:161–167
Spahn-Langguth H, Langguth P (2001) Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur J Pharm Sci 12:361–367
Cascorbi I (2006) Role of pharmocogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 112:457–473
Sikic BL (1999) Modulation of multidrug resistance: a paradigm for translational clinical research. Oncology 3:183–187
Sharom FJ, Yu X, Lu P et al. (1999) Interaction of the p-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in the isolated membranes, reconstituted systems and intact cells. Biochem Pharmacol 58:571–586
Motterlini R, Foresti R, Bassi R et al. (2000) Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. Free Radic Biol Med 28:1303–1312
May LA, Tourkin E, Hoffman SR et al. (2005) Detection and quantitation of curcumin in mouse lung cell cultures by matrix-assisted laser desorption ionization time of flight mass spectrometry. Anal Biochem 337:62–69
Shao ZM, Shen ZZ, Liu CH et al. (2002) Curcumin exerts multiple suppressive effects on human breast carcinoma cells. Int J Cancer 98:234–240
Anto RJ, Mukhopadhyaya A, Denning K, Aggarwal B (2002) Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis 23:143–150
Rao CV, Rivenson A, Simi B et al. (1995) Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res 55:259–266
Huang MT, Lou YR, Ma W et al. (1994) Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res 54:5841–5847
Shukla Y, Arora A, Taneja P (2002) Antimutagenic potential of curcumin on chromosomal aberrations in Wistar rats. Mutat Res 515:197–202
Ikezaki S, Nishikawa A, Furukawa F et al. (2001) Chemopreventive effects of curcumin on glandular stomach carcinogenesis induced by N-methyl-N′-nitro-N-nitrosoguanidine and sodium chloride in rats. Anti-Cancer Res 21:3407–3411
Sharma RA, Ireson CR, Verschoyle et al. (2001) Effects of dietary curcumin on glutathione S-transferase and malondialdehyde-DNA adducts in rat liver and colon mucosa: relationship with drug levels. Clin Cancer Res 7:1542–1548
Ireson C, Orr S, Jones DL, Verschoyle R et al. (2001) Characterization of metabolites of the chemopreventive agent curcumin in humans and rat hepatocytes and in rat plasma and evaluation of their ability to inhibit cyclooxygenase-2 expression. Cancer Res 61:1058–1064
Holder GM, Plummer JL, Ryan AJ (1978) The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat. Xenobiotica 8:761–768
Wahlstrom B, Blennow G (1978) A study on the fate of curcumin in the rat. Acta Pharm Toxicol 43:86–92
Cheng AL, Lin JK, Hsu MM et al. (1998) Phase I chemoprevention clinical trial of curcumin. Proc Am Soc Clin Oncol 17:558a
Sharma RA, McLelland HR, Hill KA et al. (2001) Pharmacodynamic and pharmacokinetic study of oral curcuma extract in patients with colorectal cancer. Clin Cancer Res 7:1894–1900
Limtrakul P, Jorearware W, Anuchapreeda S (1998) The effects of curcumin on the proliferation of cancer cell lines. Chiang Mai Med Bull 38:55–61
Mehta K, Pantazis P, McQueen T, Aggarwal BB (1997) Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines. Anti-Cancer Drug 8:470–481
Songyot A, Pranee L, Melissa MS (2002) Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol 64:573–582
Limtrakul P, Anuchapreeda S, Buddhasukh D (2004) Modulation of human multidrug-resistance MDR-1 gene by natural curcuminoids. BMC Cancer 4:13–18
Limtrakul P, Anuchapreeda S, Lipigorngoson S, Dunn FW (2001) Inhibition of carcinogen induced c-Ha-ras and c-fos proto-oncogenes expression by dietary curcumin. BMC Cancer 1:1–7
Rao CV, Rivenson A, Simi B, Reddy BS (1995) Chemoprevention of colon cancer by dietary curcumin. Ann NY Acad Sci 768:201–204
Limtrakul P, Lipigorngoson S, Namwong O, Apisariyakul A, Dunn FW (1997) Inhibitory effect of dietary curcumin on skin carcinogenesis in mice. Cancer Lett 116:197–203
Werner W, Annika B, Thomas G (2005) The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen. Pharm Res 22:728–735
Westphal K, Weinbrenner A, Giessmann T (2000) Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin Pharmacol Ther 68:345–355
Oertel R, Richter K, Gramatte T (1998) Determination of drugs in biological fluids by high-performance liquid chromatography with on-line sample processing. J Chromatogr A 797:203–209
Terhaag B, Gramatte T, Richter K (1989) The biliary elimination of the selective beta-receptor blocking drug talinolol in man. Int J Clin Pharmacol Ther Toxicol 27:170–172
Lennernas, H, Regardh CG (1993) Evidence for an interaction between the beta-blocker pafenolol and bile salts in the intestinal lumen of the rat leading to dose-dependent oral absorption and double peaks in the plasma concentration-time profile. Pharm Res 10:879–883
Barnwell SG, Laudanski T, Dwyer M (1993) Reduced bioavailability of atenolol in man: the role of bile acids. Int J Pharm 89:245–250
Yao H-M, Chiou WL (2006) The complexity of intestinal absorption and exsorption of digoxin in rats. Int J Pharm 322:79–86
Schwarz UI, Gramatte T, Krappweis J (2000) P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int J Clin Pharmacol Ther 38:161–167
Schwarz UI, Gramatte T, Krappweis J (1999) Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans. Clin Pharmacol Ther 65:283–290
Budihna MV, Strojan P (1993) Ca2+ channel antagonists inhibit the intestinal absorption of digoxin in the guinea-pig. Eur J Pharmacol 230:301–305
Su SF, Huang JD (1996) Inhibition of the intestinal digoxin absorption and exsorption by quinidine. Drug Metab Dispos 24:142–147
Cvetkovic M, Leake B, Fromm MF (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866–871
Spahn-langguth H, Baktir G, Radschuweit A (1998) P-glycoprotein transporters and the gastrointestinal tract: evaluation of thepotential in vivo relevance of in vitro data employing talinolol as model compound. Int J Clin Pharmacol Ther 36:16–24
Asai A, Miyazawa T (2000) Occurrence of orally administered curcuminoid as glucuronide and glucuronide/sulfate conjugates in rat plasma. Life Sci 67:2785–2793
Wang YJ, Pan MH, Cheng AL, Lin LI, Ho YS, Hsieh CY, Lin JK (1997) Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 15:1867–1876
Srinivas RV, Middlemas D, Flynn P (1998) Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob Agents Chemother 42:3157–3162
Gutmann H, Fricker G, Drewe J (1999) nteractions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 56:383–389
Acknowledgements
The authors are very grateful to Cordanum Arzneimittelwerk Dresden GmbH (Dresden, Germany), for generously providing the talinolol reference standard and tablet formulations. The authors are sincerely thankful to Dr. Fischer Claudia for his generous help in mailing the package of talinolol reference and tablet preparation. Professor Yang Li-Ying is also appreciated for her help on the present subject.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Juan, H., Terhaag, B., Cong, Z. et al. Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers. Eur J Clin Pharmacol 63, 663–668 (2007). https://doi.org/10.1007/s00228-007-0298-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-007-0298-0